Identification of women at risk of hereditary breast-ovarian cancer among participants in a population-based breast cancer screening.
Genetic counselling/testing
Genetic literacy
Hereditary breast–ovarian cancer
Population-based breast cancer screening
Risk assessment
Women information
Journal
Familial cancer
ISSN: 1573-7292
Titre abrégé: Fam Cancer
Pays: Netherlands
ID NLM: 100898211
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
03
12
2020
accepted:
13
10
2021
pubmed:
21
10
2021
medline:
22
6
2022
entrez:
20
10
2021
Statut:
ppublish
Résumé
Women attending mammography screening may benefit from family history (FH) assessment for the identification of Hereditary Breast Ovarian Cancer (HBOC). Few studies explored the efficacy of tailored educational interventions in driving the attention on FH-associated risk among these women. To compare the efficacy of two educational tools in increasing attention towards FH, 6.802 women with a negative mammography were randomized to receive a note on FH of breast/ovarian cancer (letter A, n = 3.402) or a note with details on possible implication of FH patterns (letter B, n = 3.200). Upon women's request, a brief questionnaire was administered on phone at the Screening Unit (S.U.) to select those eligible for an in-depth FH evaluation at the Genetic Unit (G.U.). Each affected relative was scored 1-3 according to type of cancer, age at diagnosis, gender, position in the family tree. In all, 401 women contacted the S.U.: 244 (6.6%) in group A and 177 (5.2%) in group B (adjOR 1.27; 95%CI 1.03-1.56). FH scored ≥ 3 for 164 women: 177 (47.5%) in group B and 224 (35.7%) in group A, (adjOR 1.59, 95%CI 1.06-2.38). The G.U. traced and interviewed 148 women, 65 (43.9%) were offered an in-person consultation: 38 attended and 30 were eligible for testing. A test was performed for 24 women: no BRCA pathogenic variant was found. Among mammographic screening attendees, educational material with a simple description of FH may improve self-referral of women deserving an in-depth evaluation for HBOC identification. Additional educational efforts are needed to enhance the efficiency of the intervention.
Identifiants
pubmed: 34669096
doi: 10.1007/s10689-021-00281-x
pii: 10.1007/s10689-021-00281-x
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
309-318Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Masala G, Ambrogetti D, Assedi M, Bendinelli B, Caini S, Palli D (2017) Mammographic breast density and breast cancer risk in a Mediterranean population: a nested case-control study in the EPIC Florence cohort. Breast Cancer Res Treat 164:467–473. https://doi.org/10.1007/s10549-017-4274-9
doi: 10.1007/s10549-017-4274-9
pubmed: 28478611
Bravi F, Decarli A, Russo AG (2018) Risk factors for breast cancer in a cohort of mammographic screening program: a nested case-control study within the FRiCaM study. Cancer Med 7:2145–2152. https://doi.org/10.1002/cam4.1427
doi: 10.1002/cam4.1427
pubmed: 29654663
pmcid: 5943434
Martin LJ, Melnichouk O, Guo H, Chiarelli AM, Hislop TG, Yaffe MJ, Minkin S, Hopper JL, Boyd NF (2010) Family history, mammographic density, and risk of breast cancer. Cancer Epidemiol Biomark Prev 19:456–463. https://doi.org/10.1158/1055-9965.EPI-09-881
doi: 10.1158/1055-9965.EPI-09-881
Engmann NJ, Golmakani MK, Miglioretti DL, Sprague BL, Kerlikowske K (2017) Breast cancer surveillance consortium. Population-attributable risk proportion of clinical risk factors for breast cancer. JAMA Oncol 3:1228–1236. https://doi.org/10.1001/jamaoncol.2016.6326
doi: 10.1001/jamaoncol.2016.6326
pubmed: 28152151
pmcid: 5540816
Collaborative Group on Hormonal Factors in Breast Cancer (2001) Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358:1389–1399. https://doi.org/10.1016/S0140-6736(01)06524-2
doi: 10.1016/S0140-6736(01)06524-2
Shiyanbola OO, Arao RF, Miglioretti DL, Sprague BL, Hampton JM, Stout NK, Kerlikowske K, Braithwaite D, Buist DSM, Egan KM, Newcomb PA, Trentham-Dietz A (2017) Emerging trends in family history of breast cancer and associated risk. Cancer Epidemiol Biomark Prev 26:1753–1760. https://doi.org/10.1158/1055-9965.EPI-17-0531
doi: 10.1158/1055-9965.EPI-17-0531
Hu C, Polley EC, Yadav S, Lilyquist J, Shimelis H, Na J, Hart SN, Goldgar DE, Shah S, Pesaran T, Dolinsky JS, LaDuca H, Couch FJ (2020) The contribution of germline predisposition gene mutations to clinical subtypes of invasive breast cancer from a clinical genetic testing cohort. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djaa023 .
US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Doubeni CA, Epling JW Jr, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB (2019) Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US preventive services task force recommendation statement. JAMA 322:652–665. https://doi.org/10.1001/jama.2019.10987
doi: 10.1001/jama.2019.10987
Kast K, Rhiem K, Wappenschmidt B et al (2016) Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer. J Med Genet 53:465–471. https://doi.org/10.1136/jmedgenet-2015-103672
doi: 10.1136/jmedgenet-2015-103672
pubmed: 26928436
Azzollini J, Scuvera G, Bruno E, Pasanisi P, Zaffaroni D, Calvello M, Pasini B, Ripamonti CB, Colombo M, Pensotti V, Radice P, Peissel B, Manoukian S (2016) Mutation detection rates associated with specific selection criteria for BRCA1/2 testing in 1854 high-risk families: a monocentric Italian study. Eur J Intern Med 32:65–71. https://doi.org/10.1016/j.ejim.2016.03.010
doi: 10.1016/j.ejim.2016.03.010
pubmed: 27062684
Lauby-Secretan B, Scoccianti C, Loomis D, Benbrahim-Tallaa L, Bouvard V, Bianchini F, Straif K (2015) Breast-cancer screening—viewpoint of the IARC Working Group. N Engl J Med 372:2353–2358. https://doi.org/10.1056/NEJMsr1504363
doi: 10.1056/NEJMsr1504363
pubmed: 26039523
Dimitrova N, Saz Parkinson Z, Bramesfeld A, Uluturk Tekin A, Bocchi G, Pylkkanen L, Lopez Alcalde J, Neamtiu L, Ambrosio M, Deandrea S, Lerda D (2016) European guidelines for breast cancer screening and diagnosis—The European Breast Guidelines. EUR 28360 EN. Luxembourg (Luxembourg): Publications Office of the European Union. JRC104007
Marmot M, Altman D, Cameron D et al (2013) The benefits and harms of breast cancer screening: an independent review. Br J Cancer 108:2205–2240. https://doi.org/10.1038/bjc.2013.177
doi: 10.1038/bjc.2013.177
pubmed: 23744281
pmcid: 3693450
Puliti D, Duffy SW, Miccinesi G, de Koning H, Lynge E, Zappa M, Paci E; EUROSCREEN Working Group (2012) Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review. J Med Screen 19(Suppl 1):42–56. https://doi.org/10.1258/jms.2012.012082
doi: 10.1258/jms.2012.012082
Bulliard JL, Beau AB, Njor S, Wu WY, Procopio P, Nickson C, Lynge E (2021) Breast cancer screening and overdiagnosis. Int J Cancer. https://doi.org/10.1002/ijc.33602
doi: 10.1002/ijc.33602
pubmed: 33872390
Lowery JT, Byers T, Hokanson JE, Kittelson J, Lewin J, Risendal B, Singh M, Mouchawar J (2011) Complementary approaches to assessing risk factors for interval breast cancer. Cancer Causes Control 22:23–31. https://doi.org/10.1007/s10552-010-9663-x
doi: 10.1007/s10552-010-9663-x
pubmed: 20978835
Halapy E, Chiarelli AM, Klar N, Knight JA (2005) Accuracy of breast screening among women with and without a family history of breast and/or ovarian cancer. Breast Cancer Res Treat 90:299–305. https://doi.org/10.1007/s10549-004-5168-1
doi: 10.1007/s10549-004-5168-1
pubmed: 15830144
Blanch J, Sala M, Ibáñez J, Domingo L, Fernandez B, Otegi A, Barata T, Zubizarreta R, Ferrer J, Castells X, Rué M, Salas D; INCA Study Group (2014). Impact of risk factors on different interval cancer subtypes in a population-based breast cancer screening programme. PLoS ONE. 9(10):e110207. https://doi.org/10.1371/journal.pone.0110207 .
Evans DG, Donnelly LS, Harkness EF, Astley SM, Stavrinos P, Dawe S, Watterson D, Fox L, Sergeant JC, Ingham S, Harvie MN, Wilson M, Beetles U, Buchan I, Brentnall AR, French DP, Cuzick J, Howell A (2016) Breast cancer risk feedback to women in the UK NHS breast screening population. Br J Cancer 114:1045–1052. https://doi.org/10.1038/bjc.2016.56
doi: 10.1038/bjc.2016.56
pubmed: 27022688
pmcid: 4984905
TBST study group. Tailored screening for breast cancer in premenopausal women (TBST) https://clinicaltrials.gov/ct2/show/ NCT02619123.
My Pebs international randomized study comparing personalized, risk-stratified to standard breast cancer screening in women aged 40-70. ClinicalTrials.gov Identifier: NCT03672331 http://www.MyPeBS.eu/
Cortesi L, Baldassarri B, Ferretti S, Razzaboni E, Bella M, Bucchi L, Canuti D, De Iaco P, De Santis G, Falcini F, Galli V, Godino L, Leoni M, Perrone AM, Pignatti M, Saguatti G, Santini D, Sassoli de’Bianchi P, Sebastiani F, Taffurelli M, Tazzioli G, Turchetti D, Zamagni C, Naldoni C (2020) A regional population-based hereditary breast cancer screening tool in Italy: first 5-year results. Cancer Med. https://doi.org/10.1002/cam4.2824
doi: 10.1002/cam4.2824
pubmed: 32045136
pmcid: 7131858
van Erkelens A, Sie AS, Manders P, Visser A, Duijm LE, Mann RM, Ten Voorde M, Kroeze H, Prins JB, Hoogerbrugge N (2017) Online self-test identifies women at high familial breast cancer risk in population-based breast cancer screening without inducing anxiety or distress. Eur J Cancer 78:45–52. https://doi.org/10.1016/j.ejca.2017.03.014
doi: 10.1016/j.ejca.2017.03.014
pubmed: 28412588
Wernke K, Bellcross C, Gabram S, Ali N, Stanislaw C (2019) Impact of implementing B-RSTTM to screen for hereditary breast and ovarian cancer on risk perception and genetic counseling uptake among women in an academic safety net hospital. Clin Breast Cancer 19:e547–e555. https://doi.org/10.1016/j.clbc.2019.02.014
doi: 10.1016/j.clbc.2019.02.014
pubmed: 31005475
Meinert CL (1986) Clinical trials: design, conduct and analysis. . Oxford University Press, Oxford
doi: 10.1093/acprof:oso/9780195035681.001.0001
Varesco L, Viassolo V, Viel A, Gismondi V, Radice P, Montagna M, Alducci E, Della Puppa L, Oliani C, Tommasi S, Caligo MA, Vivanet C, Zuradelli M, Mandich P, Tibiletti MG, Cavalli P, Lucci Cordisco E, Turchetti D, Boggiani D, Bracci R, Bruzzi P, Bonelli L (2013) Performance of BOADICEA and BRCAPRO genetic models and of empirical criteria based on cancer family history for predicting BRCA mutation carrier probabilities: a retrospective study in a sample of Italian cancer genetics clinics. Breast 22:1130–1135. https://doi.org/10.1016/j.breast.2013.07.053
doi: 10.1016/j.breast.2013.07.053
pubmed: 24011770
Kne A, Zierhut H, Baldinger S, Swenson KK, Mink P, Veach PM, Tsai ML (2017) Why is cancer genetic counseling underutilized by women identified as at risk for hereditary breast cancer? Patient perceptions of barriers following a referral letter. J Genet Couns 26:697–715. https://doi.org/10.1007/s10897-016-0040-0
doi: 10.1007/s10897-016-0040-0
pubmed: 27826805
Silver E, Wenger N, Xie Z, Elashoff D, Lee K, Madlensky L, Trent J, Petruse A, Johansen L, Naeim A (2019) Implementing a population-based breast cancer risk assessment program. Clin Breast Cancer 19:246–253
doi: 10.1016/j.clbc.2019.02.009
Krakow M, Ratcliff CL, Hesse BW, Greenberg-Worisek AJ (2017) Assessing genetic literacy awareness and knowledge gaps in the US population: results from the health information national trends survey. Public Health Genomics 20:343–348. https://doi.org/10.1159/000489117
doi: 10.1159/000489117
pubmed: 29852491
Krakow M, Rising CJ, Trivedi N, Yoon DC, Vanderpool RC (2020) Prevalence and correlates of family cancer history knowledge and communication among US adults. Prev Chronic Dis 17:E146. https://doi.org/10.5888/pcd17.200257
doi: 10.5888/pcd17.200257
pubmed: 33211995
pmcid: 7735478